Experts & media roundtable briefing: Getting things done to tackle superbugs: moving from talk to action

The AMR Industry Alliance has contracted think tank and advisory firm SustainAbility to deliver its first progress report, which has been informed by the analysis of aggregated responses from participating companies.

The survey was developed in consultation with experts from the AMR Industry Alliance Board and working groups of representatives of member companies. The report compiles the results of how members are meeting the Alliance’s goals, in four different areas: Research and Science, Access, Appropriate Use, and Environment.

The report is based on analysis of the data collected as well as insights from the Alliance’s Working Groups and SustainAbility’s own analysis. It is the first attempt to aggregate and report the diverse industry activities relating the development of AMR.

This first report will be published on 18 January 2018 and will serve to benchmark our progress, set targets for the future and identify gaps where further efforts may be required.

Moderator Prof. David Heymann, Head of the Centre on Global Health Security at Chatham House
Welcome and introduction
  • Dame Sally Davies, Chief Medical Officer UK, Member of the United Nations Interagency Coordination Group on Antimicrobial Resistance (IACG)
  • Dr. Jeremy Farrar, Director, Wellcome Trust
Superbugs, all talk no action?
  • Thomas Cueni, Director General, IFPMA, Chair, AMR Industry Alliance
  • Sanjeev K Singh, Medical Superintendent, The Amrita Institute of Medical Sciences or ‘Amrita Hospital’


The AMR Industry Alliance progress report SustainAbility report overview with focus on Research & Science, Access, Appropriate Use, Environment highlighting achievements and challenges
How can we move the needle? Biotech, diagnostics, generics, R&D pharma companies highlighting achievements and challenges:

  • Gary M Cohen, Executive Vice President, Global Health and President, BD Foundation
  • Steve Bates, Chief Executive, BIA
  • Lucas Wiarda, Global Strategy Director Drug Products, DSM Sinochem
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline


 Closing remarks – Prof David Heymann
when 12/01/2018
where London
RSVP info@amrindustryalliance.org